Sequential insulin strategies in type 2 diabetes.

Slides:



Advertisements
Similar presentations
Insulin Therapy. Insulin Treatment (when?) Any Glucose Level Age Rapid onset Weight loss Tablets fail Pregnancy Illness Ketoacidosis Pancreat-ectomy.
Advertisements


Diabetes (abridged!). Who needs screening for DM? Age >45 Obese – BMI >25 1 st degree relative with DM Racial groups: –African American –Hispanic American.
Factors Associated With Weight Gain in People With Type 2 Diabetes Starting on Insulin Featured Article: Beverley Balkau, Philip D. Home, Maya Vincent,
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia.
Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections.
Pramlintide Advisory Committee July 26, 2001 Symlin ® Amylin Pharmaceuticals New Drug Application (21-332) Advisory Committee Meeting Bethesda, Maryland.
Clinical Protocol Using Insulin Pump Easy Guideline for Initiating Insulin Pumps on Type 2 Diabetes Patients.
Insulin therapy.
Case Studies on Insulin Initiation
LONG TERM BENEFITS OF ORAL AGENTS
GENE THERAPY FOR DIABETES Lindsey Rowbotham Period 7.
Clinical Update in Type 2 Diabetes A Case Discussion Dr. Yancey R. Holmes, MD, FACE Ohio Valley Endocrinology.
Consider this Combo: GLP-1 Receptor Agonists and Basal Insulin Matt Heinsen, PharmD PGY2 Pharmacotherapy Resident Butler University & Community Health.
Basal Bolus: The Strategy for Managing All Diabetes Fall, 2003 Paul Davidson, MD, FACE Atlanta Diabetes Associates Atlanta, Georgia.
Insulin Initiation and Titration for Family Physicians: Case Study #2: Andy Alice Y.Y. Cheng, MD FRCPC Peter Lin, MD CCFP.
Insulin Initiation In Primary Care Dr Arla Ogilvie Endocrinologist Watford General Hospital West Herts Hospitals NHS Trust.
Type I Diabetes Mellitus
INSULIN PUMPS Shelby Polk DNP, FNP-BC, CDE. 2 MANAGEMENT OF DIABETES IN SCHOOLS Exercise Legal Rights Health & Learning Nutrition Insulin Administration.
Source:
Quality of Life Matters NOT TOO HIGH… NOT TOO LOW… A PLAN FOR OPTIMIZING DIABETES MANAGEMENT IN NURSING HOMES 5. Insulin: Part 1.
Small concise points on Insulin
Fig. 2. Change in (A) glycosylated hemoglobin (HbA1c) and (B) fasting plasma glucose (FPG). Group A: oral hypoglycemic agents (OHAs; sulfonylurea+metformin.
Fig. 1. Study flow chart. Group A: intensifying oral hypoglycemic agents (OHAs; sulfonylurea+metformin dose titration or fixed-dose combination added to.
Glycemia Treatment Strategies Used In ACCORD
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2006 American Medical Association. All rights reserved.
Neal B, et al. Diabetes Care 2015;38:403–411
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
Components of a CGM record over a 3
Program Goals. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding.
T1DM: Insulin Initiation
New Patient-Friendly Options for Managing Insulin Dosing
Diabetes Self-Management Education and Support: Component of Standard Diabetes Care 1, 2 “… Ongoing patient self-management education and support are.
Modulation of the intensiveness of glucose lowering in type 2 diabetes
Diabetes management (Updated guidelines)
Options for Combination Therapy in Type 2 Diabetes: Comparison of the ADA/EASD Position Statement and AACE/ACE Algorithm  Timothy Bailey, MD  The American.
Athena Philis-Tsimikas, MD  The American Journal of Medicine 
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.
Insulin Use in Primary Care: Practice Challenges
Treatment Pathway for Adults with Type 1 Diabetes
Practical diagram of typical insulin dose requirements for type 1, type 2, and other forms of diabetes mellitus. Practical diagram of typical insulin dose.
Antihyperglycemic therapy in type 2 diabetes: general recommendations (17). Antihyperglycemic therapy in type 2 diabetes: general recommendations (17).
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Individualizing Insulin Therapy in the Management of Type 2 Diabetes
Younger Patients With Type 1 Diabetes: Can We Optimize Their Insulin Therapy?
Approach to starting and adjusting insulin in type 2 diabetes.
Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.
Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.
Trends in the relative contribution of each second-line diabetes medication class, by quarter, as a percent of all second-line prescribing, 2011–2015.
Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.
Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.
ADA/EASD general recommendations for type 2 diabetes management (1).
INSULINS Dr.R.Sajjad december INSULINS Dr.R.Sajjad december 2018.
Exogenous CRP administration causes fasting hyperglycemia and hyperinsulinemia without altering body composition. Exogenous CRP administration causes fasting.
The effect of sulfonylurea (glibenclamide = glyburide) and metformin therapy on the plasma HbA1c concentration in newly diagnosed T2DM subjects in UKPDS.
GLP-1 and gastrin combination therapy restores normoglycemia in NOD mice. GLP-1 and gastrin combination therapy restores normoglycemia in NOD mice. Beginning.
Antihyperglycemic therapy in type 2 diabetes: general recommendations (22). Antihyperglycemic therapy in type 2 diabetes: general recommendations (22).
Insulin Delivery Systems Atlanta Diabetes Associates
Clinical responses to therapy from baseline to week 24 and end point with last observation carried forward (LOCF). Clinical responses to therapy from baseline.
Distribution of daily frequency of BGM
Insulin in Type 2 Diabetes
Initiation and adjustment of insulin regimens.
An insulin simplification regimen: from multiple injections to once-daily long-acting (basal) insulin plus noninsulin agents. *Basal insulins: glargine.
Fresh perspectives ON BASAL Insulins in diabetes care
Time course of daily basal and mealtime insulin dose (A), glycated hemoglobin (B), laboratory-measured clinic FPG (C), prebreakfast SMPG (D), SMPG profiles.
A: Glucose levels during basal-bolus and SSI treatment.
Nutrition Interventions to Improve Quality of Care
Presentation transcript:

Sequential insulin strategies in type 2 diabetes. Sequential insulin strategies in type 2 diabetes. Basal insulin alone is usually the optimal initial regimen, beginning at 0.1–0.2 units/kg body weight, depending on the degree of hyperglycemia. It is usually prescribed in conjunction with one to two noninsulin agents. In patients willing to take more than one injection and who have higher HbA1c levels (≥ 9.0%), twice-daily premixed insulin or a more advanced basal plus mealtime insulin regimen could also be considered (curved dashed arrow lines). When basal insulin has been titrated to an acceptable fasting glucose but HbA1c remains above target, consider proceeding to basal plus mealtime insulin, consisting of one to three injections of rapid-acting analogs (see text for details). A less studied alternative—progression from basal insulin to a twice-daily premixed insulin—could be also considered (straight dashed arrow line); if this is unsuccessful, move to basal plus mealtime insulin. The figure describes the number of injections required at each stage, together with the relative complexity and flexibility. Once a strategy is initiated, titration of the insulin dose is important, with dose adjustments made based on the prevailing glucose levels as reported by the patient. Noninsulin agents may be continued, although insulin secretagogues (sulfonylureas, meglitinides) are typically stopped once more complex regimens beyond basal insulin are utilized. Comprehensive education regarding self-monitoring of blood glucose, diet, exercise, and the avoidance of, and response to, hypoglycemia are critical in any patient on insulin therapy. Mod., moderate. Silvio E. Inzucchi et al. Diabetes Spectr 2012;25:154-171 ©2012 by American Diabetes Association